ACE-031 (1mg) Research Compound: A Soluble ActRIIB Receptor for Myostatin & Muscle Atrophy Studies

If your research investigates the molecular regulation of skeletal muscle mass, myostatin signalling, or the pathophysiology of muscle‑wasting disorders, ACE-031 (1mg) research compound — also known as Ramatercept or Myostatin inhibitory peptide 7 — offers a precisely defined and extensively studied biological tool. ACE‑031 is a recombinant fusion protein consisting of the extracellular domain of the activin receptor type IIB (ActRIIB) linked to the Fc region of human immunoglobulin IgG1.

As a soluble ligand trap, it binds to and neutralises myostatin (GDF‑8) and other negative regulators of muscle mass, effectively blocking signalling through the ActRIIB receptor. This mechanism promotes skeletal muscle growth and has been the subject of numerous preclinical studies and clinical trials. This makes ACE-031 (1mg) research compound a valuable tool for laboratories investigating muscle biology, cachexia, sarcopenia, muscular dystrophy, and the broader TGF‑β superfamily signalling pathways.

At Chinese Grey Peptides, we supply high‑purity ACE-031 (1mg) research compound to research institutions and wholesale buyers across the United Kingdom, France, Germany, Spain, Sweden, Italy, and the USA. Every batch is lyophilised, HPLC‑verified to ≥98% purity, and accompanied by a Certificate of Analysis (COA), ensuring your investigations into muscle regulation, myostatin signalling, and regenerative biology begin with uncompromising quality.

What Is ACE‑031 and How Does It Work?

To fully appreciate the research potential of ACE-031 (1mg) research compound, it is essential to understand its biochemical structure and the precise mechanism by which it modulates muscle growth signalling.

The ActRIIB‑Fc Fusion Protein

ACE‑031 is a recombinant fusion protein composed of the extracellular domain of the human activin receptor type IIB (ActRIIB) fused to the Fc region of human IgG1. Its sequence is a 24‑amino‑acid peptide: Ala‑Trp‑Arg‑Gln‑Asn‑Thr‑Arg‑Tyr‑Ser‑Arg‑Ile‑Glu‑Ala‑Ile‑Lys‑Ile‑Gln‑Ile‑Leu‑Ser‑Lys‑Leu‑Arg‑Leu‑NH₂. It has a CAS number of 1621169‑52‑5 and a molecular weight of approximately 2,956.49 Da for the peptide core, or 77.24 kDa for the full fusion protein.

Mechanism of Action: Ligand Trap and Myostatin Neutralisation

The biological activity of ACE‑031 (1mg) research compound is mediated through its function as a soluble ligand trap:

• High‑Affinity Ligand Binding: ACE‑031 binds to myostatin (GDF‑8) and other negative regulators of muscle mass, including activin A. By acting as a soluble decoy receptor, it sequesters these ligands before they can engage endogenous ActRIIB receptors on muscle cells.

• Inhibition of ActRIIB Signalling: By preventing ligand‑receptor interaction, ACE‑031 blocks the downstream signalling cascade that would otherwise inhibit muscle growth. This includes the SMAD signalling pathway, which is central to the regulation of muscle‑specific gene expression.

• Promotion of Muscle Growth: The net effect is the promotion of skeletal muscle growth through increased muscle fibre cross‑sectional area and lean body mass. Importantly, this growth occurs independent of fibre‑type expression.

Research Note: Clinical Development and Regulatory Status

ACE‑031 has been the subject of extensive preclinical and clinical investigation. In a Phase 1 study of healthy postmenopausal women, a single dose of ACE‑031 (3 mg/kg) resulted in statistically significant increases in mean total body lean mass (3.3%) and thigh muscle volume (5.1%) at day 29. The compound was generally well‑tolerated, with a mean half‑life of 10‑15 days.

ACE‑031 has received FDA Orphan Drug designation for the treatment of Duchenne Muscular Dystrophy (DMD) and has been evaluated in Phase 2 clinical trials for DMD. However, it is not FDA‑approved for therapeutic use and is supplied strictly for research purposes only.

Key Research Applications for ACE-031 (1mg)

ACE‑031 (1mg) research compound is a versatile tool with applications spanning several domains of biomedical research.

1. Muscle Biology & Myostatin Signalling Research

As a potent myostatin inhibitor, ACE‑031 is an essential tool for studying the molecular regulation of muscle mass. Research applications include:

• Myostatin Signalling Pathways: Investigating how myostatin and activin A signal through ActRIIB to regulate muscle growth, differentiation, and atrophy.

• SMAD Pathway Analysis: Studying the downstream SMAD signalling cascade and its role in muscle‑specific gene expression.

• Muscle Fibre Type Studies: Investigating how ACE‑031 promotes muscle growth independent of fibre‑type expression.

2. Muscle Wasting & Atrophy Research

ACE‑031 is frequently used in models of muscle‑wasting conditions:

• Cachexia Models: Investigating the peptide’s potential to mitigate muscle loss in cancer cachexia and other wasting syndromes.

• Sarcopenia Research: Studying age‑related muscle loss and the potential for intervention.

• Duchenne Muscular Dystrophy (DMD): ACE‑031 has been evaluated in Phase 2 clinical trials for DMD and received FDA Orphan Drug designation.

3. Protein‑Protein Interaction & Receptor Binding Studies

ACE‑031 serves as a valuable tool for studying ligand‑receptor interactions:

• Competitive Binding Assays: Characterising the affinity and specificity of myostatin and activin A binding to ActRIIB.

• Surface Plasmon Resonance (SPR): Quantitative assessment of binding kinetics and inhibitory potency.

• Structure‑Activity Relationship (SAR) Studies: Informing the rational design of next‑generation myostatin antagonists.

4. TGF‑β Superfamily Signalling Research

ACE‑031 is widely applied in the analysis of TGF‑β superfamily signalling:

• Transcriptional Networks: Mapping the gene expression networks responsible for muscle‑specific gene regulation.

• Cross‑Talk Studies: Assessing the interaction between myostatin inhibition and other growth factor pathways.

• Cellular Fate Decisions: Investigating how TGF‑β signalling influences muscle cell proliferation, differentiation, and hypertrophy.

5. In Vitro Muscle Tissue Models

ACE‑031 is frequently incorporated into in vitro muscle tissue models:

• Altered Myostatin Environments: Simulating physiological or pathological conditions relevant to muscle wasting, hypertrophy, or adaptation.

• Drug Discovery: Screening and validating novel myostatin antagonists and muscle‑building compounds.

Chemical & Physical Specifications for ACE-031 (1mg)

Accurate characterisation of ACE‑031 (1mg) research compound is essential for reproducible experimental design.

Note: The 1 mg mass refers to the weight of the fusion protein in its lyophilised form. ACE‑031 is a research‑grade reagent for laboratory use only (RUO). Not for human consumption. ACE‑031 is not FDA‑approved for therapeutic use.

Reconstitution & Handling Protocol for ACE‑031 (1mg)

Proper reconstitution of ACE‑031 (1mg) research compound is critical for maintaining its structural integrity and biological activity. The product can be reconstituted with sterile PBS or saline.

Step 1 – Preparation

• Bring the sealed ACE‑031 vial and your chosen diluent (sterile PBS or sterile saline) to room temperature.

• Clean your work surface with 70% ethanol and lay out sterile syringes, alcohol wipes and a clean work mat.

Step 2 – Reconstitution

• Draw your desired volume of diluent into a sterile syringe. A common starting concentration for research applications is 1 mg per 0.1‑0.2 mL of diluent, yielding a 5‑10 mg/mL stock solution.

• Slowly inject the diluent against the inner glass wall. Do not spray directly onto the lyophilised powder.

• Gently swirl the vial until the solution is clear and fully dissolved. Do not shake vigorously.

Step 3 – Aliquoting & Storage

• Immediately after dissolution, aliquot the reconstituted ACE‑031 into single‑use sterile vials.

• Store aliquots at –20°C. Avoid repeated freeze‑thaw cycles.

• Once thawed, store at 2‑8°C and use within a short period.

Concentration Reference Table for ACE-031 (1mg)

Adjust diluent volume based on your experimental requirements.

Storage & Stability Guidelines for ACE-031 (1mg)

Why Choose Chinese Grey Peptides for ACE‑031 (1mg)?

As an authentic licensed peptide supplier based in the USA, we supply ACE‑031 (1mg) research compound and a wide range of research‑grade compounds under rigorous quality assurance protocols, fully aligned with Google’s E‑E‑A‑T standards (Experience, Expertise, Authoritativeness, Trustworthiness).

• Verified Purity: Independent HPLC analysis with purity guaranteed ≥98% for every batch.

• GMP‑Compliant Manufacturing: All compounds are synthesised under strict quality control conditions.

• Full Traceability: Batch‑specific Certificates of Analysis (COA) are available for every order.

• Wholesale Supply: We serve research institutions, laboratories, and wholesale buyers across the UK, EU, and USA with flexible volume pricing and reliable logistics.

• USA‑Based Regulatory Compliance: All products are supplied strictly as research‑grade reagents for laboratory use only (RUO). ACE‑031 is not FDA‑approved for therapeutic use.

Researchers across the United States—including those at leading institutions—trust us for fast domestic delivery, transparent documentation and professional technical support.

FAQ: ACE-031 (1mg) Research Compound

 What is ACE-031 (1mg) research compound?
ACE‑031 (Ramatercept, Myostatin inhibitory peptide 7) is a recombinant fusion protein consisting of the extracellular domain of the activin receptor type IIB (ActRIIB) linked to the Fc region of human IgG1. It functions as a soluble ligand trap that binds to and neutralises myostatin and other negative regulators of muscle mass.

 What is the sequence and molecular weight of ACE‑031?
The peptide core sequence is Ala‑Trp‑Arg‑Gln‑Asn‑Thr‑Arg‑Tyr‑Ser‑Arg‑Ile‑Glu‑Ala‑Ile‑Lys‑Ile‑Gln‑Ile‑Leu‑Ser‑Lys‑Leu‑Arg‑Leu‑NH₂. Its molecular formula is C₁₃₃H₂₂₇N₄₃O₃₃, with a molecular weight of approximately 2,956.49 Da for the peptide core, or 77.24 kDa for the full fusion protein.

What are the primary research applications for ACE-031 (1mg)?
ACE‑031 is used in muscle biology and myostatin signalling research, muscle wasting and atrophy studies (cachexia, sarcopenia, Duchenne muscular dystrophy), protein‑protein interaction and receptor binding studies, TGF‑β superfamily signalling research, and in vitro muscle tissue models.

What is the mechanism of action of ACE‑031?
ACE‑031 acts as a soluble ligand trap, binding to myostatin (GDF‑8) and activin A. By sequestering these negative regulators, it prevents them from signalling through ActRIIB receptors, thereby promoting skeletal muscle growth.

What clinical evidence supports ACE‑031’s efficacy?
In a Phase 1 study, a single dose of ACE‑031 (3 mg/kg) resulted in a 3.3% increase in total body lean mass and a 5.1% increase in thigh muscle volume. ACE‑031 has received FDA Orphan Drug designation for Duchenne Muscular Dystrophy and has been evaluated in Phase 2 clinical trials.

What purity does your ACE-031 (1mg) meet?
Our ACE‑031 is tested to ≥98% purity by HPLC. A Certificate of Analysis (COA) is supplied with every order.

 How should I reconstitute ACE-031 (1mg)?
Reconstitute with sterile PBS or sterile saline. Allow the vial to reach room temperature, then slowly inject the diluent against the inner glass wall and swirl gently. Do not shake.

 How should I store reconstituted ACE‑031?
Reconstituted ACE‑031 should be stored at 2‑8°C for short‑term use. For longer storage, aliquot immediately into single‑use vials and store at –20°C for up to 3 months. Avoid repeated freeze‑thaw cycles.

 Is ACE‑031 research compound legal to purchase in the USA?
Yes. ACE‑031 is a laboratory reagent sold for research use only (RUO). It is fully legal to purchase, possess, and use in the United States for legitimate in‑vitro or in‑vivo scientific research, provided it is not marketed with therapeutic claims. Note: ACE‑031 is not FDA‑approved for therapeutic use.

 Does Chinese Grey Peptides ship internationally?
Yes. We ship across the UK, Europe (France, Germany, Spain, Sweden, Italy), and the USA from our US warehouse. Wholesale pricing is available for bulk orders.

ACE-031 (1mg)

1. Shop Page
2. Bulk Orders Page
3. Contact Page
4. Shipping & Return Page
5. Peptide Purity Page

• PubMed ACE-031 clinical-trial reference
• PMC / Drug Testing and Analysis ACE-031 detection paper
• WADA Prohibited List page
• FDA peptide warning letter example
• Google Product Structured Data

ACE-031 (1mg)

Ships to USA, Canada, UK & Europe

Chinese Grey Peptides supports shipping to the USA, Canada, the United Kingdom, France, Germany, Spain, Sweden, Italy, and Europe where permitted.

Shipping support may include:

• Order processing updates
• Packaging support
• Tracking information where available
• Wholesale shipment planning
• Destination-based shipping review
• Customer support during transit

Shipping times may vary by order size, carrier, destination, customs process, product status, and local requirements.

Why Choose Chinese Grey Peptides?

Chinese Grey Peptides focuses on quality, support, and clear communication. We help buyers review product details before placing an order.

Customers choose us for:

• Professional supplier support
• Small and wholesale order options
• Product documentation support
• HPLC testing information where available
• Mass Spectrum documentation where available
• Protein-characterization support where available
• International shipping support
• Responsive communication
• Clear order assistance before payment

We aim to make the buying process transparent, professional, and documentation-focused.

Important Compliance Notice

ACE-031 (1mg)

ACE-031 1mg may be regulated differently depending on the country, product type, labeling, intended use, buyer type, and destination. Chinese Grey Peptides does not provide medical advice, dosing instructions, injection guidance, athletic-performance claims, muscle-growth claims, bodybuilding claims, recovery claims, fat-loss claims, disease claims, treatment claims, or personal-use recommendations.

Customers are responsible for understanding and following all local laws, import rules, prescription requirements, sport-governing rules, compounding rules, and permitted-use requirements before ordering.

From its design as a soluble ActRIIB receptor fusion protein to its well‑characterised role in neutralising myostatin and promoting skeletal muscle growth, ACE‑031 (1mg) research compound provides a precisely defined and extensively validated platform for advanced muscle biology and regenerative research.

Its ability to sequester multiple negative regulators of muscle mass, its demonstrated efficacy in preclinical and clinical studies—including significant increases in lean body mass and muscle volume—and its FDA Orphan Drug designation for Duchenne Muscular Dystrophy make it a valuable addition to any laboratory investigating muscle regulation, myostatin signalling, or muscle‑wasting disorders. By choosing high‑purity, lab‑verified ACE-031 (1mg) research compound from Chinese Grey Peptides, you ensure that your research is built on a foundation of quality, reproducibility, and scientific integrity.

Ready to advance your research with ACE-031 (1mg)? Browse our product catalogue, request a wholesale quote, or contact our support team today to discuss your laboratory’s specific needs. Place your order now and receive GMP‑grade ACE‑031 delivered directly to your facility in the USA, UK, or Europe .ACE-031 (1mg)